iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Eris Lifesciences: Need to put ‘Swiss’ Injectables deal in order

19 Mar 2024 , 10:34 AM

During its Investor meet, Eris’ mgmt highlighted company’s sharp focus on process management and doctor engagement initiatives, which has enabled the company to scale-up its acquired Derma portfolio and further strengthen its position in the Cardio-Diabetes segment. While Eris’ organic growth in India has been muted at 7- 8% over the past 2yr period owing to rationalisation of tail-end brands and product returns of expired batches, mgmt is hopeful of pick-up in organic growth driven by a robust pipeline of 26 products including potential launches of Dapagliflozin combinations, Glargine, Liraglutide over the next 12 months. Analysts of IIFL Securities factor-in the Swiss Parenterals acquisition into their estimates and expect the deal to be ~3/5% EPS accretive in FY25/26. Valuation re-rating for Eris remains contingent on pick-up in India organic growth. Maintain BUY given inexpensive valuations. Analysts of IIFL Securities TP of ₹1,060 is based on ~22x FY26 core EPS vs ~26-35x for other India-peers. 

Cleaner structure of Swiss will help to assuage investor concerns: While Eris’ Rs6.4bn acquisition of 51% stake in Swiss Parenterals (an RoW Injectables business) has raised capital allocation concerns owing to diversification away from India formulations business, analysts of IIFL Securities believe a key concern among investors has been acquisition of 19% stake in Swiss by Eris' promoter group. Mgmt seems to be evaluating the deal structure given the investor feedback and a cleaner structure (with Eris acquiring the 19% stake, which is currently proposed to be acquired by Eris' promoters) will help to address some of these concerns. 

Eris' FY29 revenue guidance of Rs50bn implies 21% revenue Cagr over FY24-29, vs analysts of IIFL Securities current estimates where they have factored-in 16% revenue Cagr to Rs42bn in FY29. Analysts of IIFL Securities FY29 revenue forecast is 18% below company's guidance, despite assuming 11-12% organic revenue Cagr in India and 20% Cagr for Swiss Parenterals, implying that Eris will be dependent on further M&A deals to meet its FY29 revenue aspiration. Mgmt indicated that India:Exports contribution to FY29 revenue will be 80:20% and Eris will continue to remain a predominantly India-focused company. 

New product launches to drive growth for Swiss: 

While Eris will leverage Swiss' portfolio to build an Injectables business in India, Swiss will focus on new launches (including OSDs from Eris) to drive growth in RoW markets. Swiss is working on Iron deficiency products (Dextran, Sucrose, Ferric Carboxy Maltose), Peptides (Semaglutide, Octreotide, Suggamadex).

Related Tags

  • Eris Lifesciences
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp